Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 Mg/Day or 20 Mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US, EFC4964) - A Randomized, Double-Blind, 3-Arm, Placebo-Controlled, Parallel-Group, Fixed-Dose, 52-Week, Multi-Center Study.

Trial Profile

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 Mg/Day or 20 Mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US, EFC4964) - A Randomized, Double-Blind, 3-Arm, Placebo-Controlled, Parallel-Group, Fixed-Dose, 52-Week, Multi-Center Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2009

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Acronyms STRATUS-US
  • Most Recent Events

    • 14 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top